Loading…
Loading grant details…
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Cincinnati Childrens Hosp Med Ctr |
| Country | United States |
| Start Date | May 01, 2021 |
| End Date | Apr 30, 2023 |
| Duration | 729 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10174193 |
PROJECT SUMMARY Myelodysplastic-syndrome (MDS) is a cancer of stem cells that form the blood.
In MDS, abnormal stem cells accumulate but are unable to make enough functional blood cells, and can eventually transform to acute myeloid leukemia (AML).
While we know that this slow transformation process starts with mutations in specific genes, we do not know why such MDS-mutation-bearing cells have a competitive advantage over normal cells. Understanding this process is fundamental to figuring out new ways to treat patients.
We have assembled a team of researchers, unique models and cutting-edge technology to determine whether infectious challenge provides a selective environment for hematopoietic clones with mutation of MDS/AML-associated genes.
We expect to determine at a single-cell level how MDS-genic mutations affect stem cell biology, and whether changes in the environment of the bone marrow help mutant stem cells generate disease.
Cincinnati Childrens Hosp Med Ctr
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant